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Abstract
 
Multiple sclerosis (MS) is a chronic demyelinating disease in which it has only recently been
suggested that damage to neuronal structures plays a key role. Here, we uncovered a link
between the release of lipid breakdown products, found in the brain and cerebrospinal fluid
(CSF) of MS patients as well as in experimental autoimmune encephalomyelitis, and neuronal
damage mediated by microglial activation. The concentrations of the breakdown product
7-ketocholesterol detected in the CSF of MS patients were capable of inducing neuronal damage
via the activation and migration of microglial cells in living brain tissue. 7-ketocholesterol rapidly
entered the nucleus and activated poly(ADP-ribose)-polymerase (PARP)-1, followed by the
expression of migration-regulating integrins CD11a and intercellular adhesion molecule 1. These
findings reveal a novel mechanism linking demyelination and progressive neuronal damage, which
might represent an underlying insidious process driving disease beyond a primary white matter
phenomenon and rendering the microglial PARP-1 a possible antiinflammatory therapeutic target.
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Introduction
 
Multiple sclerosis (MS) is a chronic demyelinating disease
in which it has only recently been suggested that damage
to neuronal structures plays a key role (1–10). In addition
to demyelination and damage to oligodendrocytes, the
primary and quantitatively dominating histopathological
characteristics of MS, axonal damage (6, 8–10), and neu-
ronal cell death (5) have recently been reemphasized in
MS patient brain tissue. Because there is evidence that the
severity of MS sometimes correlates better with neuronal
alterations than with demyelination (10), the mechanisms
linked to this neuronal pathology could serve as promising
targets for therapeutic improvements in the clinical out-
come of the disease.
During the development of MS, myelin sheaths are pref-
erentially and extensively damaged by an attack of immune
cells in multiple areas of the brain and spinal cord (11). This
attack involves the release of large amounts of free oxygen
radicals, which contribute to the radical-mediated oxidation
and breakdown of myelin (12, 13). Because cholesterol is a
major component of the myelin sheath, and cholesterol ox-
idation products are well known for exhibiting cytotoxic
effects toward blood vessels (14–16) and neurons (17–19),
we addressed the question of whether such products could
induce and maintain neuronal cell damage after the initial
immune attack in MS.
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Abbreviations used in this paper:
 
 BHT, 
 
 
 
-hydroxytoluol; CNS, central nervous
system; CSF, cerebrospinal fluid; DTT, dithiothreitol; EAE, experimental
autoimmune encephalomyelitis; GC/MS, gas chromatography/mass
spectrometry; HPLC, high performance liquid chromatography; ICAM,
intercellular adhesion molecule; iNOS, inducible nitric oxide synthase;
MS, multiple sclerosis; NF, nuclear factor; OHSC, organotypic hip-
pocampal slice culture; OND, other neurological disease; PARP,
poly(ADP-ribose)-polymerase; w.w., wet weight. 
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Materials and Methods
 
Sample Collection.
 
Serum, cerebrospinal fluid (CSF), and PBMCs
of donors were collected at the Institute of Neuroimmunology
and the Department of Neurology, University Hospital Charité,
Berlin, Germany. The study was approved by the local ethical
committee. Of the 23 patients, 11 had been diagnosed with re-
lapsing remitting MS, according to Poser’s criteria (20). The
other 12 patients had other inflammatory and noninflammatory
neurological diseases (ONDs; e.g., idiopathic epilepsy, hydro-
cephalus, migraine, trigeminal neuralgia, multiple systemic atro-
phy, cerebral infarction, torticollis, chronic headache, and poly-
neuropathy). All were newly diagnosed patients who had not
been treated before venous puncture. Fresh frozen blocks of au-
topsied brain tissue from patients with chronic active MS (
 
n 
 
  
 
3),
chronic silent MS (
 
n 
 
  
 
6), and control patients (
 
n 
 
  
 
7) were pro-
vided by C.S. Raine on dry ice (mean postmortem delay: 8.0 
 
 
 
0.0 h for patients with chronic active MS, 3.5 
 
  
 
0.9 h for patients
with chronic silent MS, and 7.6 
 
  
 
1.3 h for control patients).
Central nervous system (CNS) tissue from chronic active cases
contained established, gliotic lesions with evidence of recent in-
flammatory activity at the lesions margins, and some fresh, acute
MS lesions with edema, actively demyelinating margins rich
in inflammatory cells, and numerous hypertrophic astrocytes.
Chronic silent cases displayed lesions that were intensely gliotic
and demyelinated with little evidence of inflammation (21). The
16 brain samples were assigned numbers and studied for 7-keto-
cholesterol by investigators blinded to the code.
 
Detection of Oxysterols in the CSF.
 
Cholesterol oxidation
products in the serum and CSF of the patients were analyzed by
gas chromatography/mass spectrometry (GC/MS) as described by
Sevanian et al. (22). In brief, 5 mg/liter 5
 
 
 
-cholestane was added
as the internal standard to 200 
 
 
 
l serum or CSF, and lipids were
extracted and then fractionated by a diol column. The choles-
terol/cholesterol oxide fraction was then subjected to alkaline
hydrolysis in ether, extracted, methylated using etheral diaz-
omethane, and derivatized to trimethylsilylethers with bis(tri-
methylsilyl)-trifluoroacetamide in dimethylformamide. All extrac-
tion and derivatization procedures were performed in 0.01%
 
 
 
-hydroxytoluol (BHT) and in an argon atmosphere to prevent
further oxidation during the sample preparation for GC/MS.
Because the human CSF samples have to be subjected to diagnos-
tic investigations, BHT was added after taking the aliquot for
7-ketocholesterol analysis. Control experiments demonstrated no
differences between an immediate addition of BHT and adding
BHT before starting the extraction procedure. Samples were ana-
lyzed on a Shimadzu gas chromatograph coupled with a mass
spectrometer (180
 
 
 
C for 5 min, 4
 
 
 
C/min, and 260
 
 
 
C for 5 min),
and mass chromatograms were recorded in the mass range from
130–700 mass to charge ratio at a scan rate of three scans per sec-
ond. Peak identification was based on relative retention time and
ion mass spectrometry in comparison with external standards and
quantified by integration in relation to the internal standard.
 
Detection of 7-Ketocholesterol by High Performance Liquid Chroma-
tography (HPLC).
 
Cholesterol oxidation products were analyzed
by a reverse phase HPLC method as described by Kritharides et
al. (23) after extraction as described above. The concentrations of
total cholesterol in serum were 1.58 
 
  
 
0.32 g/liter for control pa-
tients and 1.72 
 
  
 
0.40 g/liter for MS patients. The cholesterol
concentration in the CSF was 6.83 
 
  
 
1.88 mg/liter for control
patients and 8.35 
 
  
 
2.73 mg/liter for MS patients.
 
Induction and Clinical Evaluation of Active Experimental Autoim-
mune Encephalomyelitis (EAE).
 
6–8-wk-old female SJL mice
(
 
 
 
20 g body weight; Charles River Laboratories) were immu-
 
nized s.c. with 75 
 
 
 
g proteolipid protein 139–151 (purity 
 
 
 
95%;
Pepceuticals) in 0.2 ml emulsion consisting of equal volumes of
PBS and CFA (Difco) and containing 6 mg/ml 
 
Mycobacterium tu-
berculosis
 
 H37Ra (Difco). 200 ng pertussis toxin (List Biological
Laboratories) was administered i.p. at days 0 and 2. Mice were
daily scored for EAE (24) as follows: 0, no disease; 1, tail weak-
ness; 2, paraparesis; 3, paraplegia; 4, paraplegia with forelimb
weakness or paralysis; 5, moribund or dead animals (25). Clinical
scores on separate days and mean maximal scores were calculated
by adding scores of individual mice and dividing by number of
mice in each group. All procedures were conducted according to
protocols approved by the local animal welfare committee.
 
Immunohistochemistry and Quantitative Assessment.
 
Mice killed
with narcotics were transcardially perfused with 4% paraformal-
dehyde. Horizontal 50-
 
 
 
m thick vibratome sections (Shandon)
were immersed with 3% H
 
2
 
O
 
2 
 
to quench unspecific endogenous
peroxidase activity, washed, and blocked (10% normal serum and
0.5% Triton X-100) before overnight incubation with anti-active
caspase 3 (1:100; R&D Systems). Sections were immunolabeled
using the avidin/biotinylated enzyme complex technique (ABC-
Elite; Vector Laboratories) before development with diami-
nobenzidine (brown signal) as substrate. Ig control experiments
were performed for all primary antibodies and no staining was
observed under these conditions. Section were counterlabeled by
Nissl staining. Neurons positive for active caspase 3 were counted
in brain stem sections by two independent investigators in a blind
manner. Four visual fields on both sides of the midline in the
brain stem motor area were counted for caspase-3
 
  
 
neurons using
a 
 
 
 
20 objective. The average number of neurons from three ani-
mals, with four sections analyzed per mouse, is shown as relative
to the controls in Fig. 3 a.
 
Cell Culture.
 
BV-2 microglial cells are primary mouse mi-
croglial cells immortalized by stabile transfection with the 
 
c-myc
 
-
oncogene using a J7-retrovirus (26), leading to a phenotype
functionally identical to native primary microglia (27). These
cells were cultured in DMEM medium supplemented with 16%
FCS at a density not exceeding 2 
 
  
 
10
 
5 
 
cells/ml. Microglial acti-
vation was performed by incubation with 10 
 
 
 
g/ml LPS (Sigma-
Aldrich) for 24 h. Primary neurons were prepared from 10-d-old
mice, the brain tissue were dissociated with 0.25% trypsin, cen-
trifuged at 470 
 
g
 
 for 10 min, resuspended in neurobasal medium,
plated on poly-
 
l
 
-lysin–coated 24-well plates, and incubated at
37
 
 
 
C, 5% CO
 
2 
 
and 95% air. After appearance of a confluent cell
layer, adherent glia cells will be mechanically dissolved and the
proliferation of the remaining glia cells will be inhibited by 8
 
 
 
M cytosine arabinoside for 3 d. HT22 hippocampal neurons
were cultured in DMEM medium supplemented with 10% FCS
and 8.5 g/liter glucose at a density of 10
 
5 
 
cells/ml or lower. To
investigate CD3
 
  
 
T cells and CD14
 
  
 
monocytes, PBMCs of four
healthy donors were isolated from fresh blood by Lymphoprep™
density gradient centrifugation (Nycomed Pharma AS) and sepa-
rated using immunomagnetic beads according to the manufac-
turer’s instructions (Miltenyi Biotec). For analyzing 7-ketocho-
lesterol, cells were left untreated or stimulated with 1 
 
 
 
g/ml
coated anti-CD3 (provided by Janssen-Cilag) and 25 
 
 
 
g/ml
anti-CD28 (R&D Systems) or 50 ng/ml LPS (Sigma-Aldrich).
 
Incubation of BV-2 Microglial Cells with 5-Cholesten-3
 
 
 
-Ol-7-
One (7-Ketocholesterol).
 
Murine BV-2 microglial cells, which ex-
hibit the functional features of primary microglia, were incubated
for 24 h with 0, 1, 10, and 100 mg/liter 5-cholesten-3
 
 
 
-ol-7-one
(7-ketocholesterol) at a density of 10
 
6 
 
cells/culture flask in 20 ml
DMEM medium, supplemented with 10% FCS. All experiments 
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were performed using a vehicle control. 7-ketocholesterol was
initially dissolved in ethanol, but cell culture medium containing
7-ketocholesterol was produced by completely removing the sol-
vent under a nitrogen stream and redissolving the remaining
material in cell culture medium supplemented with FCS. Imme-
diately before incubating the cell or brain tissue, the 7-ketocho-
lesterol concentration was confirmed by HPLC analysis. The ve-
hicle control was subjected to the same procedure.
 
Biochemical Analyses.
 
FACS
 
® 
 
analysis was performed with
FITC-conjugated monoclonal rat anti–mouse-CD11a, rat anti–
mouse-CD11b, rat anti–mouse-CD18, and rat anti–mouse inter-
cellular adhesion molecule (ICAM)-1 antibodies (BD Bio-
sciences). Cells were lysed by repeated freeze thawing cycles, and
then the lysates were used for experiments. Nuclei were isolated
by a modification of the method by Emig et al. (28) and lysed by
repeated freeze thawing cycles in 1 mM dithiothreitol (DTT).
Poly(ADP-ribosyl)ation activity was measured as the incorpora-
tion of radioactivity from 
 
32
 
P-NAD
 
  
 
into trichloroacetic acid-
insoluble material. The reaction mixture contained 100 mM
phosphate buffer, pH 7.8, 200 
 
 
 
M NAD
 
 
 
, 10 mM MgCl
 
2
 
, 5 mM
DTT, 1 mM DTT, 1 
 
 
 
g sonicated DNA/reaction, and 500,000
dpm 
 
32
 
P-NAD
 
  
 
(NEN Life Science Products). In vitro
poly(ADP-ribosyl)ation was detected by incubation of 2 
 
 
 
g re-
combinant poly(ADP-ribose)-polymerase (PARP)-1 expressed in
 
Escherichia coli 
 
(Qbiogene) with and without native or sonified
pcDNA3.1-vector-DNA. SDS/PAGE analysis was performed in a
12% separation gel, after which the separated proteins were trans-
blotted onto nitrocellulose membranes. The membranes were in-
cubated with antibodies directed against nuclear factor (NF)-
 
 
 
B
(p65; Upstate Biotechnology), inducible nitric oxide synthase
(iNOS; Sigma-Aldrich), and PARP (BIOMOL Research Labora-
tories, Inc.). After incubation with an appropriate peroxidase-con-
jugated secondary antibody, the blots were developed with a
chemiluminescence detection kit (Amersham Biosciences).
 
Experiments with Organotypic Hippocampal Slice Cultures
(OHSCs).
 
OHSCs were obtained by decapitating newborn
mice on the 9–10th
 
 
 
postnatal day, aseptically removing a frontal
slice of the caudal cerebrum, and transversally sectioning it at a
thickness of 350 
 
 
 
m on a sliding vibratome in MEM supple-
mented with 1% 
 
l
 
-glutamine as previously described (29).
OHSCs were cultivated in culture medium (MEM/HBSS 2:1,
25% normal horse serum, 2% 
 
l
 
-glutamine, 2.64 mg/ml glucose,
and penicillin/streptomycin) at 35
 
 
 
C with 5% CO
 
2 
 
for 10 d in
vitro to ensure a healthy organotypic microenvironment in the
middle layer, which is known to induce microglial ramification
(29). For the detection of 7-ketocholesterol after excitotoxic in-
jury, OHSCs were exposed to 50 
 
 
 
M NMDA, after which the
medium was removed and the tissue was harvested for further
analysis. 3 d after transfer of microglial cells (BV-2 microglial
cells, pcDNA3.1.-BV-2 microglial cells, or antisense-PARP-1-
pcDNA3.1-BV-2 microglial cells, respectively; reference 27) in
the presence or absence of 10 mg/liter 7-ketocholesterol, cell
death in the sites of neuronal injury (neuronal cell layers of CA
and DG) was detected by staining with 5 
 
 
 
g/ml propidium io-
dide for 4 h (27) and was quantified in the cryostat sections (29).
Neurons were identified by double fluorescence staining against
the neuronal nuclear protein NeuN (1:1,000; mouse anti–mouse;
Chemicon) or neurofilament (1:1,000; mouse anti–mouse;
Chemicon). Microglia were labeled immunohistochemically by
Griffonia simplicifolia isolectin IB
 
4 
 
(IB
 
4
 
)-FITC (diluted 1:40;
Sigma-Aldrich) in 0.1 M phosphate buffer, pH 6.8, and 0.5% Tri-
ton X-100. The material was examined with a BX-50 micro-
scope (Olympus). Fluorescence was evaluated with the following
 
filters: for FITC, excitation filter 470–490 nm, barrier filter 515–
550 nm; for rhodamine, excitation filter 520–550 nm, barrier fil-
ter 580 nm. Site-specific migration of BV-2 microglial cells into
the regions of neuronal layers of OHSCs were quantified as the
ratio between the cell count of Mini-Ruby–prelabeled vector-
control-BV-2 microglia cells or antisense-PARP-1-BV-2 micro-
glial cells in the neuronal layers (27).
 
Results
 
Accumulation of 7-Ketocholesterol in the CSF of MS Patients.
 
We analyzed serum and CSF of patients with MS and pa-
tients with ONDs using a GC/MS method for identifica-
tion and quantification of cholesterol oxides (22). All pa-
tients were newly diagnosed and had not received any
previous treatment. Cholesterol oxides were detected in
high concentrations in the CSF of MS patients, whereas
OND patients revealed only very low or no detectable
amounts. The major cholesterol oxidation product in the
CSF was identified as 5-cholesten-3
 
 
 
-ol-7-one (7-keto-
cholesterol) by ion mass spectrometry in comparison with
known standards. We found a distinctly elevated concen-
tration of 7-ketocholesterol in the CSF of MS patients
compared with OND patients (Fig. 1 a). The CSF/serum
ratio (Fig. 1 b) indicates that the detected 7-ketocholesterol
originated from the CNS and not the blood system (16, 22,
30). In fact, we did not find direct release of 7-ketocholes-
terol from activated mononuclear cells (CD3
 
  
 
T cells acti-
vated with CD3/CD28, CD14
 
  
 
monocytes activated with
LPS) up to 72 h after stimulation, indicating brain tissue as
the source of 7-ketocholesterol (unpublished data). Al-
though serum analysis by isotope dilution mass spectrome-
try (31) revealed lower 7-ketocholesterol concentrations,
the detected serum concentrations in our study were fully
comparable to the concentrations previously reported for
healthy human subjects in studies using the GC/MS
method by Sevanian et al. (22), as well as gas chromatogra-
phy with flame ionization detection (32, 33).
 
Accumulation and Degradation of 7-Ketocholesterol in Brain
Tissue.
 
Cholesterol is not only a component of myelin,
but is also localized within the outer cell membrane of neu-
rons and nonneuronal cells, where its breakdown products
can easily diffuse into the intercellular space (34) and the
CSF. Therefore, in MS it might be possible that either the
downstream release of large amounts of oxygen free radicals
after neuronal injury or the oxidative burst by inflammatory
cells contribute to the oxidative damage (35–37) and break-
down of cholesterol in the cell membrane. Thus, using
HPLC (23), we analyzed the CSF of patients with neurode-
generative diseases without any clinically detectable neu-
roinflammation (e.g., Alzheimer’s, systemic atrophy), of pa-
tients with primary and severe neuroinflammatory diseases
(e.g., severe meningitis and viral encephalitis), of control pa-
tients without any CNS disease (e.g., prolapsed interverte-
bral disc, peripheral polyneuropathy), and of MS patients
(Fig. 1 c). Although no accumulation of 7-ketocholesterol
could be detected in patients with neurodegeneration (mean 
 
 
 
0.47 mg/liter plus 0.47 mg/liter SEM, 
 
n 
 
  
 
6), it was found 
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in substantially high concentrations in the CSF of patients
with severe neuroinflammation (mean 
 
  
 
5.55 mg/liter plus
0.63 mg/liter SEM, 
 
n 
 
  
 
6), and of patients with MS
(mean 
 
  
 
8.50 mg/liter plus
 
 
 
0.29 mg/liter SEM, 
 
n 
 
  
 
11).
This suggests that 7-ketocholesterol accumulates after dam-
age to nonneuronal cells rather than after primary neuronal
damage. Interestingly, neuronal damage has also been ob-
served in primary inflammatory CNS diseases like meningi-
tis (38), but it follows the initial nonneuronal pathology.
To find out whether 7-ketocholesterol is produced
during active inflammation, we assessed the concentration
of 7-ketocholesterol in an inflammatory environment in
living brain tissue. We used OHSCs incubated with mi-
croglial cells with and without stimulation by LPS, allow-
 
ing these cells to invade living brain tissue. Inflammation
itself might lead directly to either an additional endoge-
nous release of 7-ketocholesterol from brain tissue in-
duced by invading microglial cells, a disturbance of sup-
posed detoxifying metabolisms in brain tissue by these
microglial cells, or both. In these experiments, endoge-
nous 7-ketocholesterol strongly accumulated in living
brain tissue invaded by microglial cells (Fig. 2 a), but dis-
appeared quickly after reaching a maximum after 8 h, in-
dicating the existence of a 7-ketocholesterol degrading
system. In brain tissue incubated with 10 mg/liter 7-keto-
cholesterol, 
 
 
 
68 plus 7.8% of the initial concentration
could be detected after 3 d of incubation, but disappeared
completely after 3 d in brain tissue invaded by microglial
Figure 1. Assessment of 5-cholesten-3 -ol-7-one
(7-ketocholesterol) in the CSF of patients with MS
and in neural cell and tissue cultures. (a) Detection of
5-cholesten-3 -ol-7-one (7-ketocholesterol) in the
CSF of patients with MS. Absolute 7-ketocholesterol
concentrations detected by GC/MS are demonstrated
for each individual MS or OND patient. Means are
given as   SEM. MS patients: mean   7.37 mg/liter,
SEM 0.32 mg/liter, n   11; OND patients: mean  
0.53 mg/liter, SEM 0.08 mg/liter, n   12. (b) Detec-
tion of 5-cholesten-3 -ol-7-one (7-ketocholesterol)
in the CSF of patients with MS. CSF/serum ratio of
7-ketocholesterol detected in the CSF and in serum
from MS and OND patients are demonstrated for
each individual patient. MS patients: mean   33.4  
5.12 SD, n   11; OND patients: mean   0.53  
0.08 SD, n   12. (c) 5-cholesten-3 -ol-7-one (7-
ketocholesterol) in the CSF of patients with nonde-
myelinating neurological diseases (neuroinflammatory
diseases, neurodegenerative diseases, and control patients
without CNS disease). Absolute 7-ketocholesterol
concentrations in the CSF detected by HPLC are
demonstrated for each group. Means are given as  
SD. Patients with MS: mean   8.50 mg/liter   0.29
mg/liter, n   11; neuroinflammatory diseases: mean  
5.55 mg/liter   0.63 mg/liter, n   6; patients with
neurodegenerative diseases: mean   0.47 mg/liter  
0.47 mg/liter, n   6; patients without CNS disease:
mean   0.47 mg/liter   0.47 mg/liter, n   6.Diestel et al. 1733
cells (2.1   0.4%), implying rapid degradation by micro-
glial cells. LPS activation of microglial cells resulted in a
fast and substantial accumulation of 7-ketocholesterol in
the brain tissue, but also in an even faster disappearance af-
terwards (Fig. 2 a). The rapid decline of the 7-ketocholes-
terol content in OHSCs invaded by microglial cells sug-
gests that microglial cells could be capable of both uptake
and degradation of 7-ketocholesterol. In fact, we could
show that HT22 neuronal cells were not capable of de-
grading 7-ketocholesterol, although we revealed strong
metabolism in BV-2 microglial cells induced by LPS (Fig.
2 c). This demonstrates a dual role of microglial cells in
the inflammatory environment: induction of accumula-
tion and degradation of 7-ketocholesterol. This fast and
activation-dependent metabolism of 7-ketocholesterol
could also explain why we could not detect a release by
activated inflammatory cells in culture.
Moreover, coincubation with the selective extracellular
free radical scavenger DMPO distinctly reduced 7-keto-
cholesterol release (Fig. 2 b), particularly after incubation
with LPS-activated microglial cells, demonstrating its oxy-
gen radical-derived origin. These experiments indicate that
7-ketocholesterol in brain tissue derives from the oxidative
attack of microglial cells.
To investigate the contribution of neuronal and non-
neuronal cells to the 7-ketocholesterol release from living
organotypic brain slices after invasion of microglial cells,
we compared the release of 7-ketocholesterol from these
slices with the release from slices after elimination of via-
ble neurons by incubation with 50  M NMDA for 24 h.
The complete elimination of viable cells in the neuronal
layers was confirmed by propidium iodide staining. The
observed difference between the 7-ketocholesterol re-
lease from the slice cultures with ( 220  g/mg protein;
Figure 2. Accumulation and degradation of 7-ketocho-
lesterol in brain tissue. (a) Production of 7-ketocholesterol
in hippocampal brain slice cultures after invasion of microglial
cells. Concentration of 7-ketocholesterol in the living
brain tissue of hippocampal slice cultures after transfer of
105 BV-2 microglial cells with ( BV-2  LPS) or without
( BV-2) previous activation by LPS in comparison to
untreated controls (control). Data are given as mean, SD  
10%, n   6. (b) Influence of oxygen radicals on the con-
centration of 7-ketocholesterol in hippocampal brain slice
cultures. Concentration of 7-ketocholesterol in the living
brain tissue of hippocampal slice cultures 4 h after transfer
of 105 BV-2 microglial cells with (LPS) or without (con)
previous activation by LPS or incubation with 75 mM of
the extracellular radical scavenger, DMPO. Data are given
as mean   SD, n   6. *, P   0.005. (c) Degradation of
7-ketocholesterol. Degradation of 7-ketocholesterol by BV-2
microglial cells with ( ) or without ( ) previous activation
by LPS and HT22 hippocampal neurons ( ). Data are
given as concentrations in the cell culture supernatant.
Data are given as mean   SD, n   6. (d) Production of
7-ketocholesterol from nonneuronal components of hip-
pocampal brain slice cultures after invasion of microglial
cells. Concentration of 7-ketocholesterol in the living brain
tissue of hippocampal slice cultures after transfer of 105
LPS-activated BV-2 microglial cells (OHSC). OHSC(D),
previous elimination of living neurons by incubation with
50  M NMDA for 24 h. Data are given as mean   SD,
n   6. *, P   0.05. (e) Production of 7-ketocholesterol by
NMDA-damaged primary neurons. The release of 7-keto-
cholesterol in the culture medium after induction of neuronal
damage by 50  M NMDA is demonstrated. Data are given
as mean   SD, n   6.Cholesterol Breakdown Products during Neuroinflammation 1734
Fig. 2 d) and without viable neurons ( 185  g/mg pro-
tein; Fig. 2 d) equals the amount of 7-ketocholesterol re-
leased during the NMDA-induced death of cultivated
primary neurons ( 40  g/mg protein; Fig. 2 e). Thus,
we provide evidence for the mainly nonneuronal source
of 7-ketocholesterol that we can detect in the CSF of MS
patients.
7-Ketocholesterol in Brain Tissue Correlates with Disease Score
and Neuronal Damage During EAE. Presuming, as our
studies indicate, that 7-ketocholesterol is formed mainly
by the nonneuronal compounds of the CNS, the question
arises whether 7-ketocholesterol is also detectable in MS
brain tissue. We found  2.6 times more 7-ketocholes-
terol in patients displaying acute MS lesions than in brain
tissue of patients with chronic silent MS lesions or with-
out CNS disease (Fig. 3 a). Because postmortem oxysterol
determinations could be influenced by autolysis and au-
tooxidation, we investigated the production of 7-keto-
cholesterol in murine EAE (39, 40), a well-characterized
CD4  T cell–mediated animal disease model of relapsing
Figure 3. Accumulation of 7-ketocholesterol in CNS of MS patients and mice during EAE. (a) Detection of 5-cholesten-3 -ol-7-one (7-ketocholesterol)
in brain tissue (white matter) of patients with MS. Absolute 7-ketocholesterol concentrations detected by HPLC are demonstrated for control patients and
patients with chronic and acute MS. Control patients: mean   72.8   46.6 ng/mg w.w., n   6; chronic MS: mean   55.8   39.0 ng/mg w.w., n   6;
acute MS: mean   189.0   35.7 ng/mg w.w., n   3. *, P   0.05. (b) Concentration of 7-ketocholesterol and neuronal cell death in the brain stem motor
area and clinical disease score during the time course of EAE. Absolute 7-ketocholesterol concentrations detected by HPLC and relative amounts of active
caspase-3  neurons are demonstrated. The clinical disease score was calculated according to Brocke et al. (reference 25). All data are given as mean from
three independent experiments. (c) Active caspase-3  neurons in the brain stem motor area. Sections were counterlabeled by Nissl staining. Representative
neurons are demonstrated for the controls (left, day 0) and the clinical peak of EAE (right, arrowheads, day 12). Bar, 20  m.Diestel et al. 1735
remitting MS (41, 42). As with its human counterpart, in-
duction of EAE in susceptible strains of rodents leads to
CNS inflammation, demyelination, and neuronal pathol-
ogy (43, 44). This model system allows for correlation of
clinical disease development, neuronal pathology, and ac-
cumulation of 7-ketocholesterol during the development
Figure 4. 7-ketocholesterol induces
neuronal damage in living brain tissue
mediated by microglial cells. (a) Pictures
of propidium iodide fluorescence mi-
croscopy of the regions of neuronal injury
in the cornu ammonis and dentate gyrus
in living organotypic brain slice cultures.
Control, no treatment;  MG, 3 d after
transfer of 105  BV-2 microglial cells;
 7-KC, 3 d after incubation with
10 mg/liter 7-ketocholesterol;  7-KC
 MG, 3 d after incubation with 10 mg/
liter 7-ketocholesterol and transfer of
105 BV-2 microglial cells. (b) Neuronal
cell death after incubation with 7-keto-
cholesterol and BV-2 microglial cells.
On the left: Colocalization of propidium
iodide   cells (PI) with NeuN   cells
(NeuN; arrowheads) in the neuronal
layers of organotypic brain slice cultures
after incubation with 10 mg/liter
7-ketocholesterol and transfer of 105
BV-2  microglial cells. On the right:
Colocalization of propidium iodide 
and neurofilament  cells (PI/NF) in the
neuronal layers of the dentate gyrus
(DG) and cornu ammonis (CA). (c)
Propidium iodide  cells in the neuronal
cell layer of regions of neuronal cell
death (cornu ammonis and dentate gyrus).
Results are given as cell counts relative
to nondamaged brain tissue without
transfer of cultivated microglial cells
onto the slice surface (control, 1). Non-
viable microglial cell counts (PI /IB4
 )
were subtracted. presence, 3 d after
incubation with 10 mg/liter 7-ketocho-
lesterol;   microglia, 3 d after transfer of
105 BV-2 microglial cells.Cholesterol Breakdown Products during Neuroinflammation 1736
and clinical remission of disease. During disease develop-
ment after induction of EAE, concentrations of 7-keto-
cholesterol increased in parallel with the level of neuronal
damage in the brain stem motor area, reached their high-
est levels at the peak of the disease indicated by marked
motor deficits and highest disease score, and subsequently
decreased during clinical remission (Fig. 3, b and c). 7-keto-
cholesterol concentrations were elevated preferentially in
tissue from those brain areas predominantly affected by
EAE, such as the brain stem motor area (4.14   0.71 ng/
mg wet weight (w.w.) 7-ketocholesterol, compared with
1.48   0.16 ng/mg w.w. 7-ketocholesterol in the nonaf-
fected cortex). Interestingly, in animals that failed to re-
cover completely after EAE and showed long-term neu-
rological deficits, concentrations of 7-ketocholesterol
remained elevated (Fig. 3 b), suggesting a self-sustaining
mechanism of chronic inflammation.
Neuronal Damage by 7-Ketocholesterol in Living Brain Tissue
Is Mediated by Microglia Cells. Next, we addressed the
pathological significance of 7-ketocholesterol at the levels
found in the CSF of MS patients. Several studies have re-
ported strong neurotoxicity of cholesterol oxides in cell
culture experiments (17–19). Therefore, we investigated
whether 7-ketocholesterol may exhibit toxic effects to-
ward neurons in living brain tissue (Fig. 4, a–c). In these
studies, incubating OHSCs with 7-ketocholesterol for 3 d
only slightly increased the rate of cell death within the
neuronal layers of the hippocampus (granule cell layer of
the dentate gyrus and pyramidal cell layer of the cornu
ammonis). This finding argues against a direct neurotoxic
effect of this cholesterol breakdown product. Because the
inflammatory response in the MS brain involves activa-
tion of microglial cells, we tested the effect of 7-ketocho-
lesterol in an inflammatory environment in living brain
Figure 5. Induction of integrin and iNOS expression and activation of PARP by 7-ketocholesterol. (a) 7-ketocholesterol–induced alterations in mor-
phology, proliferation, and cell death. Amoeboid, viable, and dead BV-2 microglial cells were determined after incubation for 24 h with 0, 1, 10, and 100
mg/liter 7-ketocholesterol, which represents the concentration range from stimulating to toxic concentrations. Data are given as mean   SD, n   4. (b)
FACS® analysis of adhesion molecule expression. FACS® analysis of CD11a, CD11b, CD18, and ICAM-1 expression in BV-2 microglial cells after incu-
bation for 24 h with 0, 1, 10, and 100 mg/liter 7-ketocholesterol. Data are given as positive cells   SD, n   6. (c) iNOS protein expression in cell lysates
and translocated NF- B (p65) in lysates of isolated nuclei of BV-2 microglial cells treated with 0, 1, 10, and 100 mg/liter 7-ketocholesterol. (d) Nuclear
uptake of 7-ketocholesterol in BV-2 microglial cells with ( LPS) or without ( LPS) LPS treatment after incubation with exogenous 10 mg/liter
7-ketocholesterol. Data are given as mean   SD, n   4. (e) Activity of PARP in the nucleus of BV-2 microglial cells with ( LPS) or without ( LPS)
LPS treatment after incubation with exogenous 10 mg/liter 7-ketocholesterol. Data are given as mean   SD, n   6. (f) Activity of PARP in isolated nu-
clei of BV-2 microglial cells after incubation with 2 mg/liter exogenous 7-ketocholesterol (7-KC) or with a vehicle control (control). Activity of
poly(ADP-ribosyl)ation was measured as uptake of 32P-labeled NAD  into nuclear proteins. Data are given as mean   SD, n   6. (g) Activation of iso-
lated recombinant PARP-1 by 7-ketocholesterol is DNA dependent. Recombinant PARP-1 (recPARP) was incubated with 2 mg/liter 7-ketocholes-
terol (7-KC) in the presence of native (DNA) or sonified single strand break DNA (ssb-DNA). Activity of poly(ADP-ribosyl)ation was measured as up-
take of 32P-labeled NAD  into nuclear proteins. Data are given as mean   SD, n   9.Diestel et al. 1737
tissue. Allowing microglial cells to invade living brain tis-
sue (27, 29) in the presence of 7-ketocholesterol, we de-
tected severe neuronal damage with a significantly ele-
vated rate of cell death within the neuronal layers (Fig. 4,
a–c). The propidium iodide  dead cells colocalize exclu-
sively with NeuN  cells and moreover exhibit neurofila-
ment staining (Fig. 4 b), demonstrating that the dead cells
were neurons.
Because endogenous release of 7-ketocholesterol in
OHSCs induced by microglial cells (Fig. 2 a) was also not
capable of inducing severe neuronal damage (Fig. 4, a and c)
and 7-ketocholesterol–detoxifying metabolisms in the brain
tissue were not disturbed by microglial cells (Fig. 2, a and c),
we could rule out direct neuronal damage caused by 7-keto-
cholesterol in living brain tissue. Therefore, we came to the
conclusion that the marked neuronal damage induced by
Figure 6. Induction of adhesion molecules and
microglia-mediated inflammatory neuronal damage by
7-ketocholesterol depend on PARP-1. (a) FACS®
analysis of CD11a, CD11b, CD18, and ICAM-1 ex-
pression in control vector-transfected BV-2 microglial
cells (solid columns) and antisense PARP-1 vector-
transfected BV-2 microglial cells (open columns) after
incubation for 24 h with 10 mg/liter 7-ketocholesterol.
Data are given as positive cells   SD, n   6. (b) Site-
specific migration of BV-2 microglial cells into the
regions of neuronal layers of OHSCs. Results are given
as cell count of Mini-Ruby–prelabeled vector control
BV-2 microglia cells (vc-MG) or antisense PARP-1
BV-2 microglial cells (asPARP-1-MG) in the neuronal
layers (cornu ammonis and dentate gyrus) relative to
the cell count in the nonneuronal layers. Con (control),
without incubation with 7-ketocholesterol; 7-KC, 3 d
after incubation with 10 mg/liter 7-ketocholesterol;
  vc-MG, 3 d after transfer of 105 BV-2 control
vector-control microglial cells;   asPARP-1-MG, 3 d
after transfer of 105 antisense PARP-1 BV-2 microglial
cells. Data are given as mean from six independent
experiments     SD.  *, P    0.005. (c) Propidium
iodide  cells in the neuronal cell layer of regions of
neurodegeneration (cornu ammonis and dentate gyrus).
Results are given as cell counts relative to nondamaged
brain tissue without transfer of cultivated microglial
cells onto the slice surface. 7-KC, 3 d after incubation
with 10 mg/liter 7-ketocholesterol;   vc-MG, 3 d
after transfer of 105 BV-2 control vector-control micro-
glial cells;   asPARP-1-MG, 3 d after transfer of 105
antisense PARP-1 BV-2 microglial cells. (d) Pictures of
propidium iodide fluorescence microscopy of the regions
of neuronal injury in the cornu ammonis and dentate
gyrus in living organotypic brain slice cultures. 7-KC,
3 d after incubation with 10 mg/liter 7-ketocholesterol;
  vc-MG, 3 d after transfer of 105 BV-2 control vector-
control microglial cells;   asPARP-1-MG, 3 d after
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concentrations of 7-ketocholesterol found in the CSF of
MS patients might be mediated by microglial cells.
Activation of Microglial Cells by 7-Ketocholesterol. Our
first experiments addressing the direct effects of 7-ketocho-
lesterol on microglial cells revealed strong activation dem-
onstrated by an amoeboid morphology (Fig. 5 a), an in-
creased proliferation rate (Fig. 5 a), an increased expression
of migration-regulating integrins such as CD11a and
ICAM-1 in the FACS® analysis (Fig. 5 b), and the induc-
tion of iNOS (Fig. 5 c). This was the case with the concen-
trations found in the CSF of MS patients. However, higher
concentrations abolished proliferation and exhibited cyto-
toxicity (Fig. 5, a and b) as previously described (44). Mi-
croglial activation was observed in concentrations distinctly
below levels measured in the CSF of MS patients, but re-
flected the levels in our damage studies (Fig. 2, a–d). These
concentrations had already contributed to enhanced
CD11a and ICAM-1 expression (Fig. 5 b), and iNOS in-
duction (Fig. 5 c). Microglial activation by nontoxic levels
of 7-ketocholesterol was accompanied by translocation of
NF- B (p65; Fig. 5 c) and activation of the PARP in the
nucleus (Fig. 5 e), a 113-kD nuclear enzyme, which plays
an important regulatory role during the activation of in-
flammatory cells (27, 45) and is a strong coactivator of NF-
 B (46, 47). During this transformation of microglial cells
from a resting to a state, 7-ketocholesterol enters the nu-
cleus and is then followed by PARP activation (Fig. 5 e).
LPS activation enhances the nuclear uptake by about two-
fold (Fig. 5 d). Because PARP is already highly active in
LPS-stimulated microglial cells, this induced only a slight
increase in PARP activity (Fig. 5 e). This implies that
7-ketocholesterol does not induce the inflammatory re-
sponse of activated microglial cells, but is capable of stimu-
lating microglial cells that are primarily inactive.
Because PARP-1 plays a central role during the conver-
sion of microglial cells from the resting to the activated state
(27, 45), the question arises whether the activation of
PARP is causally linked with the translocation of 7-keto-
cholesterol into the nucleus. Thus, we incubated isolated
nuclei of ramified BV-2 microglial cells with 7-ketocholes-
terol using those concentrations as detected in the nucleus
(Fig. 5 d) and revealed an immediate and distinct increase of
nuclear poly(ADP-ribosyl)ation (Fig. 5 f). To test whether
PARP-1 is activated directly or indirectly by 7-ketocholes-
terol, we incubated isolated recombinant PARP-1 with
7-ketocholesterol in the presence and absence of DNA.
7-ketocholesterol was not capable of activating recombi-
nant PARP-1 by itself, but was capable in the presence of
DNA (Fig. 5 g). After a short lag phase of  10 min, the ex-
tent of poly(ADP-ribosyl)ation induced by 7-ketocholes-
terol in the presence of DNA reached the amount induced
by single strand break DNA, suggesting that 7-ketocholes-
terol activates PARP-1 via modification of DNA.
Down-regulation of Microglial PARP-1 Protects from 7-Keto-
cholesterol–induced Neuronal Damage in Living Brain Tissue.
Because PARP-1 has been identified as a direct down-
stream molecular target of in vivo concentrations of
7-ketocholesterol, we finally addressed the question of
whether down-regulation of PARP-1 might reduce the
microglia-mediated neuronal damage in inflamed living
brain tissue. BV-2 microglial cells stably transfected with an
antisense PARP-1-pcDNA3.1 vector (antisense-PARP-1;
reference 27) failed to respond with integrin CD11a and
ICAM-1 expression after incubation with 7-ketocho-
lesterol (Fig. 6 a). These findings indicate that 7-ketocho-
lesterol acts via a signaling pathway involving PARP-1
activation. As a consequence, although control vector–
transfected BV-2 microglial cells migrated specifically inside
the neuronal layers of living brain tissue in the presence of
7-ketocholesterol, antisense PARP-1-BV-2 microglial cells
were no longer capable of migrating site specifically (27,
29; Fig. 6 b). The invasion of antisense PARP-1-BV-2 mi-
croglial cells resulted in only 58% cell death within the
neuronal layers of the hippocampus compared with control
vector–transfected BV-2 microglial cells (Fig. 5, c and d).
This indicates that 7-ketocholesterol–induced PARP-1 ac-
tivation in migrating microglia cells contributes signifi-
cantly to the extent of neuronal damage after inflammatory
decomposition of cholesterol in myelin sheaths or cell
membranes.
Discussion
Our initial finding that the CSF of MS patients con-
tained highly elevated concentrations of the reportedly
neurotoxic cholesterol breakdown product 7-ketocholes-
terol, led us to speculate that this phenomenon plays an
important role in perpetuating neuronal damage, which is
assumed to be an important feature in the course of MS
(1–10). Here, we provide evidence that 7-ketocholesterol
released during inflammatory demyelination in the course
of MS indirectly induces neuronal damage mediated by ac-
tivated microglial cells. Transformation of microglial cells
from the resting to the activated state by 7-ketocholesterol
involved the translocation of NF- B and the activation of
PARP-1, which in turn regulates the expression of the
iNOS, CD11a, and ICAM-1, and is crucial for microglial
migration. Recently, we showed that latter mechanisms are
essential for the damaging activity of microglial cells (27).
Importantly, the cascade of 7-ketocholesterol–induced
neuronal damage via PARP-1 activation in microglial cells
obviously occurs beyond the primary MS inflammation.
Myelin damage induced by the initial T cell invasion in MS
might result in the release of 7-ketocholesterol found in
MS patients, and subsequently trigger a sustained chain of
detrimental reactions toward neurons, finally independent
of the primary event. Microglial cells are capable of acting
as the crucial mediator for this toxic effect because 7-keto-
cholesterol triggers PARP-1–dependent microglial activa-
tion and migration in the absence of a primary inflamma-
tory stimulus. Such a mechanism downstream from the T
cell response may play an important role in sustaining neu-
ronal damage in MS. On the other hand, an intervention in
these secondary inflammatory and self-sustaining damageDiestel et al. 1739
cascades offers an interesting therapeutic option to delay
the clinical onset and progress of neurodegeneration, in
particular if the primary and initial pathological event is still
unknown or difficult to treat. Here we uncovered a possi-
ble direct molecular link between demyelination and neu-
ronal damage during MS and identified the microglial
PARP-1 as crucial in this damage cascade.
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